Companies: 10,795·Total market cap: $144.5T
Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONSNASDAQHealthcare● Active
$74.48
$-0.65(-0.87%)
Market Cap$12.3B
P/E Ratio
52W High$86.74
52W Low$34.78
Overview

Ionis Pharmaceuticals, Inc. (IONS) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ions · stock forecast · 32 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 32 Wall Street analysts in the past 3 months

SellBuy

Buy

32 analysts

consensus

Rating Breakdown

Strong Buy
1
Buy
19
Hold
12
Sell
0
Strong Sell
0
Total: 32 · Buy rate: 62.5%

12-Month Price Target

High

$130

Consensus

$107

+44.0% upside

Low

$87.00

Median: $104 · Last Close: $74.48

The Ionis Pharmaceuticals, Inc. (IONS) analyst consensus is Buy, based on ratings from 32 Wall Street analysts over the past 3 months. The average 12-month IONS price target is $107.27, representing +44.0% upside from the current price of $74.48.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $107 (44.0%)

Consensus Target

$107.27

44.0% upside

High Target

$130

74.5%

Low Target

$87

16.8%

Current Price

$74.48

as of today

Based on analyst price targets, the IONS stock price prediction for the next 12 months ranges from $87 to $130. The consensus IONS price forecast of $107.27 implies 44.0% upside from the current price of $74.48.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$73.840.86%

1-day model range: $73.62–$74.06. Peak: $74.06 (-0.86%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$90+20.8%
2028$102+37.1%
2029$111+49.2%
2030$117+57.7%
2031+63.6%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%8%71%
3Buy
1Neutral
10Sell
RSI (14)50.9Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · IONS · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$74.36BUY
MA 10$75.37SELL
MA 20$75.27SELL
MA 50$74.96SELL
MA 100$77.02SELL
MA 200$73.67BUY
Current $IONS · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$74.69SELL
EMA 10$74.96SELL
EMA 20$75.10SELL
EMA 50$75.34SELL
EMA 100$75.06SELL
EMA 200$70.29BUY
Current $IONS · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-06-01
Maintains
BuyBuy
HC Wainwright & Co.2026-04-30
Maintains
BuyBuy
Barclays2026-04-30
Maintains
OverweightOverweight
RBC Capital2026-04-30
Maintains
OutperformOutperform
TD Cowen2026-04-23
Maintains
BuyBuy
Morgan Stanley2026-04-21
Maintains
OverweightOverweight
B of A Securities2026-04-09
Maintains
BuyBuy
Barclays2026-03-26
Maintains
OverweightOverweight
HC Wainwright & Co.2026-03-25
Maintains
BuyBuy
Needham2026-03-25
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Ionis Pharmaceuticals, Inc. (IONS) stock. Of the recent 238 rating actions, 18 were upgrades and 9 were downgrades. 32 analysts currently cover IONS.

Analyst Recommendation Trends

Buy ratings312
Hold ratings00
Sell ratings00

IONS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$890M

↓ 58.3% YoY

Revenue Next Year

$1.5B

↑ 67.8% YoY

EPS This Year

$-3.61

EPS Next Year

$-1.17

↓ 67.7% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast IONS EPS of $-3.61 for the current fiscal year, based on estimates from 11 analysts. The IONS revenue forecast is $890M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The IONS stock forecast is supported by two independent data sources: analyst consensus ratings from 32 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IONS price target is $107.27 (+44.0% upside), with an analyst consensus of Buy.

The IONS short-term stock prediction for tomorrow is $73.84 (-0.86%). The IONS stock price prediction for 2027 estimates an average of $90. The IONS stock prediction for 2030 projects a range of $114–$121.

Ionis Pharmaceuticals, Inc. trades on NASDAQ under the ticker IONS. The IONS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

IONS forecast · 8 questions

According to 32 Wall Street analysts, the average 12-month IONS price target is $107.27, with a high forecast of $130.00 and a low of $87.00. The median price target is shown in the chart above when available. This implies +44.0% potential upside from the current price of $74.48.

IONS price targetWhat is IONS price targetIONS analyst price targetIONS 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.